The Patent Finder

Cipla Limited

66 patents currently held · Updated Nov 21, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20
Ending by 2030
Sep 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Stabilized liquid fosaprepitant formulations (US 10,307,432) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 1 fee due Feb 27, 2027
    The maintenance fee for Ketorolac for the treatment of cancer (US 10,391,080) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 1 fee due Mar 24, 2027
    The maintenance fee for Pharmaceutical antiretroviral composition (US 10,420,727) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Thienopyridine derivative for the treatment of hepatitis C infections (US 10,471,048) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 2 fees due Jun 3 to 10, 2027 · next Jun 3
  • 1 fee due Jul 5, 2027
    The maintenance fee for Antiviral phosphonate analogues and process for preparation thereof (US 9,227,990) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
  • 1 fee due Aug 23, 2027
    The maintenance fee for Antibacterial aminoglycoside analogs (US 9,266,919) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
  • 1 fee due Sep 19, 2027
    The maintenance fee for Stable pharmaceutical formulations of pemetrexed (US 11,931,362) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
  • 1 fee due Nov 17, 2027
    The maintenance fee for Anti-retroviral combination (US 9,339,470) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,403,844Rifaximin
In force
 · Medium confidence
In forceMedium confidence
US 9,877,953Rifaximin
In force
 · Low confidence
In forceLow confidence
US 10,702,505Rifaximin
In force
 · Low confidence
In forceLow confidence
US 12,109,200Rifaximin
In force
 · Low confidence
In forceLow confidence
US 8,822,424Antibacterial aminoglycoside analogs
In force
 · USPTO record
In forceUSPTO record
US 9,266,919Antibacterial aminoglycoside analogs
In force
 · USPTO record
In forceUSPTO record
US 9,688,711Antibacterial aminoglycoside analogs
In force
 · USPTO record
In forceUSPTO record
US 11,117,915Antibacterial aminoglycoside analogs
In force
 · USPTO record
In forceUSPTO record
US 8,633,234Rifaximin
In force
 · High confidence
In forceHigh confidence
US 9,993,560Rifaximin Complexes
In force
 · High confidence
In forceHigh confidence
10 of 66 patents shown.
Pro members see all 66.
Pro members: see all 66 patents
Also on record, not counted in the 66: 3 patents in force now held by others · 104 lapsed for an unpaid fee · 29 ended at full term · 2 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 7 abandoned · 100 no status recorded

Showing 1 to 10 of 112, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/892,191Synthesis of Antibacterial Aminoglycoside AnalogsSep 20, 2024Pending
18/648,027Apr 26, 2024No status recorded
18/142,909May 3, 2023No status recorded
18/301,643Apr 17, 2023No status recorded
17/974,804Oct 27, 2022No status recorded
17/950,642Sep 22, 2022No status recorded
18/691,556Solid State Forms of RelugolixAug 17, 2022Pending
17/724,554Apr 20, 2022No status recorded
18/282,007Long Acting Injectable Compositions of Cariprazine or its Pharmaceutically Acceptable SaltsMar 15, 2022Abandoned
18/548,691Solid State Forms of 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC Acid or Its Pharmaceutically Acceptable Salts and Polymorphs ThereofFeb 25, 2022Pending
10 of 112 applications shown.
Pro members see all 112 published applications.
Pro members: see all 112 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited